Ep126: DA Wallach on Becoming a Biotech VC

Episode Summary

Executive Summary: D.A. Wallach traces his path from Wisconsin and Harvard humanities to music, Spotify, and biotech investing, showing how curiosity, interdisciplinary thinking, and long-term orientation shaped his VC strategy. He argues biotech is where major health gains will come from, but policy, incentives, and capital formation must evolve to fund innovation and make therapies broadly accessible.

Main Topics: Early life, family influences, and outsider identity (Priority: 5/5): Wallach grew up in Appleton and Milwaukee, shaped by a lawyer father, a finance-industry mother, and early experiences as a social outsider that made him comfortable challenging norms. Harvard, African American studies, and interdisciplinary learning (Priority: 5/5): At Harvard he pursued African American studies after being inspired by Cornel West and later Henry Louis Gates, emphasizing that understanding complex systems requires interdisciplinary study and curiosity. Music career and lessons from the industry (Priority: 4/5): Wallach’s success as a musician touring with major acts and later working at Spotify taught him about business models, incentives, disruption, and building products that serve both consumers and creators. Entry into investing and discovery of biotech (Priority: 5/5): He began making small personal investments in disruptive companies, then moved into healthcare via telemedicine before concluding that biotech breakthroughs—not delivery reform alone—would drive meaningful health impact. Biotech venture strategy at Time BioVentures (Priority: 5/5): Wallach describes Time BioVentures as backing exceptional founders in therapeutics, diagnostics, research tools, and care models, favoring enduring companies with founder ownership and mission-driven scale. Policy, pricing, and capital formation in biotech (Priority: 4/5): He argues that healthcare costs are mostly driven by delivery, not drugs, but policy decisions like pricing rules can distort investment incentives, especially for small-molecule development. Long-term innovation and the need for more capital (Priority: 5/5): Wallach’s long-term thesis is that biotech can transform medicine and eventually obsolete parts of the current healthcare system, but only if more capital is attracted to the sector through better financial engineering and public understanding.

Key Arguments: Wallach’s outsider upbringing and humanities background helped him become comfortable crossing disciplines and asking unconventional questions. His exposure to Cornel West and Henry Louis Gates fostered an interdisciplinary mindset that later proved useful in investing. Music and Spotify taught him how technology can shift incentives to create better outcomes for both producers and consumers. Healthcare delivery is structurally constrained by misaligned incentives, so it will change slowly compared with biotech product breakthroughs. Biotech innovations like cures and true prevention can create faster, larger system-wide change than incremental delivery reforms. Successful biotech investing requires deep scientific fluency, but also patience, learning, and a willingness to remain a beginner. Wallach believes great companies are usually founded by unique entrepreneurs with long-term missionary zeal, not by venture firms. Venture creation can limit founder ownership and deter the kind of ambitious entrepreneurs he wants to back. Policy choices—especially around drug pricing and access—shape investment incentives and can steer capital away from certain modalities. The biotech sector needs far more capital if it is to finance the wave of innovations already emerging from science and engineering.

Data Points: Inaugural Time BioVentures fund size: $100 million - Wallach describes Time BioVentures as investing from its first fund Early personal investment size: $10,000 to $30,000 per investment - He says his budget before launching a larger fund was limited to a few small bets per year Approximate number of early investments per year: 3 investments a year - Wallach explains his constrained personal venture activity Spotify-style consumer music spend: $120 per year - He notes that a $10/month streaming subscription equals $120 annually Average pre-streaming music spend: about $60 per year - Wallach says the average fan spent this much before streaming Time period of music-to-investing transition: 2011 to 2015 - He places his growing investment activity in this period Touring duration: about 3 years - Wallach says he toured nearly nonstop after college Early telemedicine investment: Doctor on Demand - His first healthcare investment and an early telemedicine company Biotech venture target: 10x larger in a decade or two - Wallach says he wants the biotech VC market to be much larger

Pivotal Quotes: "If they're successful, you'd want to own them forever." — D.A. Wallach: Describing the kind of enduring biotech companies Time BioVentures wants to back "I want cures ... to put out of business our dysfunctional health care system." — D.A. Wallach: His long-term view that breakthrough medicines, not incremental system fixes, are the real solution "The secret of, I think, venture capital is that your results are significantly determined by your deal flow." — D.A. Wallach: Explaining why founder quality and access to exceptional entrepreneurs matter most

Implications: Listeners should see biotech as a long-game field where scientific, financial, and policy literacy matter. For the industry, Wallach’s view implies more founder-friendly capital, better public understanding, and policy reforms are needed to unlock innovation at scale.